Yahoo Web Search

Search results

1. Sarepta Therapeutics near Columbus, OH

   • 

   • A
     Sarepta Therapeutics

     Chemical & Allied Product

     5200 Blazer Pkwy, Dublin, OH · (614) 766-3296
     
     Website
   Add or update your business

2. www.sarepta.comSarepta Therapeutics | Biopharmaceutical Company for Rare ...

   www.sarepta.com

   • Cached

   Sarepta is a global biotech company that develops gene therapy, RNA technologies, and gene editing for rare neuromuscular and central nervous system diseases. Learn about their science, pipeline, treatments, and careers.

   • Investors

     Sarepta Therapeutics Announces Inducement Grants Under...

     Events & Presentations

     · Press Releases

     · SEC Filings

     · Patients Can't Wait for The Next Breakthrough in Medical Research. So Neither Will We

     · Analyst Coverage

     · FAQs

   • Leadership

     "I approach my work every day with an open mind, a...

     Douglas S. Ingram

     · Ryan E. Brown, JD

   • Limb-girdle Muscular Dystrophy

     Sarepta’s gene therapy program in development uses distinct...

   • Charcot-Marie-Tooth Disease

     This gene therapy program, which targets CMT1A, the major...

   • 

     Newsroom
   • 

     Join Us
   • 

     About Us
   • Our Disease Areas
   • Our Science
   • Our Products & Pipeline

3. www.sarepta.com › about-usAbout Our Company | Sarepta Therapeutics

   www.sarepta.com › about-us

   • Cached

   Sarepta is a global biotechnology company that aims to engineer precision genetic medicine for rare diseases that devastate lives and futures. Learn about their mission, leadership, patient affairs, grants, and locations.

4. investorrelations.sarepta.com › news-releases › newsSarepta Therapeutics Announces FDA Approval of ELEVIDYS, the ...

   investorrelations.sarepta.com › news-releases › news

   • Cached

   Jun 22, 2023 · ELEVIDYS is the first gene therapy to treat Duchenne muscular dystrophy, a rare genetic disease that causes muscle degeneration. The FDA approved ELEVIDYS based on increased expression of ELEVIDYS micro-dystrophin protein in skeletal muscle, but requires a confirmatory trial.

5. Top Stories

   • 
     YAHOO!Finance

     Earnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

     Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) just released its quarterly report and things are looking bullish. It was

     4 days ago

   • 

     The Motley Fool on MSN.com

     Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript

     1 week ago

   • 

     Business Insider

     What Analysts Are Saying About Sarepta Therapeutics Stock

     6 days ago

   • 

     The Motley Fool on MSN.com

     1 Top Growth Stock to Buy and Hold for 10 Years

     1 week ago

   • YAHOO!Finance

     Bullish Sarepta Therapeutics Insiders Loaded Up On US$13.3m Of Stock

     2 weeks ago

   View all

6. Videos

   • 

     1:25:42

     youtube.com

     Sarepta Therapeutics: LGMD Diagnosis and Gene Treatment

     Aug 12, 2020

     679 Views

   • 

     0:33

     facebook.com

     For those individuals living with... - Sarepta Therapeutics

     Dec 21, 2023

     966 Views

   • 

     15:44

     youtube.com

     Approved Therapies - Sarepta Therapeutics

     Sep 2, 2020

     483 Views

   View all

7. en.wikipedia.org › wiki › Sarepta_TherapeuticsSarepta Therapeutics - Wikipedia

   en.wikipedia.org › wiki › Sarepta_Therapeutics

   • Cached

   Douglas S. Ingram. ( CEO & President) Revenue. $301 Million (2018) Website. www .sarepta .com. Sarepta Therapeutics, Inc. ( Nasdaq : SRPT) is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States.

   • Revenue: $301 Million(2018)
   • Key people: Douglas S. Ingram, (CEO & President)

   • Headquarters: Cambridge

8. finance.yahoo.com › quote › SRPTSarepta Therapeutics, Inc. (SRPT) - Yahoo Finance

   finance.yahoo.com › quote › SRPT

   • Cached

   Find the latest Sarepta Therapeutics, Inc. (SRPT) stock quote, history, news and other vital information to help you with your stock trading and investing.

9. People also ask

   Who is Sarepta?

   • Sarepta, a global biopharmaceutical company, has locations throughout the world. We have an audacious vision: to forever change the course of genetic disease. Learn more about Sarepta, and our commitment to develop precision genetic medicine for rare genetic conditions.

   About Our Company | Sarepta Therapeutics

   www.sarepta.com/about-us

   See all results for this question

   What is Sarepta's efficacy supplement?

   • "We are pleased to announce that FDA has accepted and filed Sarepta’s Efficacy Supplement to evaluate broadening the approved indication of ELEVIDYS by removing age and ambulation restrictions and converting the approval from accelerated to traditional,” said Doug Ingram, president and chief executive officer, Sarepta Therapeutics.

   Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy

   investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-us-fda-acceptance-efficacy

   See all results for this question

   Is Sarepta a revolution?

   • Some see slow and steady scientific progress. We see a revolution. Sarepta is a global biotechnology company on an urgent mission: engineer precision genetic medicine to reclaim futures otherwise impacted or cut short by rare diseases.

   Sarepta Therapeutics | Biopharmaceutical Company for Rare

   www.sarepta.com/

   See all results for this question

   Why should you join Sarepta?

   • Armed with the most advanced science in genetic medicine, we are in a daily race to rescue lives otherwise stolen by rare disease. At Sarepta, every day is another twenty-four hours to stand up for patients, advance technology, challenge convention, and drag tomorrow into today.

   About Our Company | Sarepta Therapeutics

   www.sarepta.com/about-us

   See all results for this question

10. www.sarepta.com › newsroomNews & Press Releases | Sarepta Therapeutics

    www.sarepta.com › newsroom

    • Cached

    Find the latest news and updates from Sarepta, a biotech company developing gene therapy for rare neuromuscular diseases. Read press releases, stories and perspectives from advocates, innovators, patients and scientists.

11. investorrelations.sarepta.com › news-releases › newsSarepta Therapeutics Announces U.S. FDA Acceptance of an ...

    investorrelations.sarepta.com › news-releases › news

    • Cached

    Feb 16, 2024 · Sarepta Therapeutics announced that the FDA has accepted and filed its efficacy supplement to convert the accelerated approval of ELEVIDYS, a gene therapy for Duchenne muscular dystrophy (DMD), to a traditional approval. The supplement aims to remove the age and ambulation restrictions and broaden the indication to include all DMD patients with a confirmed mutation in the DMD gene.